Clinical Trials Logo

Allergic Contact Dermatitis clinical trials

View clinical trials related to Allergic Contact Dermatitis.

Filter by:

NCT ID: NCT00445029 Recruiting - Clinical trials for Allergic Contact Dermatitis

Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation

Start date: March 2007
Phase: N/A
Study type: Observational

The current knowledge of the pathophysiology of allergic contact dermatitis is based on the murine model. In this model, CD8+ T cells are effector cells, and CD4+ T cells regulate the response by limiting the expansion of CD8+ T cells. The goal of this study is to characterize the pathophysiology of contact dermatitis, with patients allergic to para-phenylenediamine (PPD). We suppose that the CD8+ T cells are the effectors of the allergic contact dermatitis, although the regulator cells belong to the LT CD4+ population. We will test our hypothesis on blood samples, and cutaneous biopsies of patients allergic to PPD.

NCT ID: NCT00133341 Completed - Clinical trials for Allergic Contact Dermatitis

Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate

Start date: April 2005
Phase: Phase 2
Study type: Interventional

It is the purpose of this study to determine the concentration of 3 allergens (goldnatriumthiosulphate, methyldibromoglutharonitrile [MDBGN], parthenolide) for diagnosing allergic contact dermatitis.

NCT ID: NCT00132600 Completed - Clinical trials for Allergic Contact Dermatitis

Clinical Evaluation of Bacitracin

Start date: April 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish a concentration of a bacitracin-patch for diagnosing allergic contact dermatitis.